ArticleJTCVS techniques2025
Supradiaphragmatic Roux-en-Y jejunal reconstruction after extended total gastrectomy for gastroesophageal adenocarcinoma.
Article in JTCVS techniques, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fully robotic extended total gastrectomy with transthoracic long Roux limb reconstruction.Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Surgical management of gastroesophageal junction adenocarcinoma extending into both the esophagus and the stomach often requires distal esophagectomy and total gastrectomy (extended total gastrectomy). Roux-en-Y jejunal conduits are commonly used for reconstruction; however, concerns exist regarding the ability to obtain adequate length for a supradiaphragmatic anastomosis. Methods: This retrospective study included patients with esophagogastric adenocarcinoma who underwent extended total gastrectomy at our institution between 2016 and 2023. Clinicopathologic characteristics were analyzed descriptively. Quality of life was assessed using a Likert scale survey. The Roux-en-Y jejunal conduit was constructed by dividing the second and occasionally third jejunal arterial branches to obtain sufficient length. Disease-free survival (DFS) was defined as the time from surgery to recurrence or death from any cause. Results: Overall, 29 patients were included. The median patient age was 64 years, and 83% of the patients received neoadjuvant therapy. Five patients (17%) had an anastomotic leak, and 9 (31%) had grade 3-4 complications. The median DFS was 4.5 years; 72% of patients had resumed a regular diet by 3 months. Compared with standard esophagectomy patients at our institution, gastrectomy patients had a longer median length of stay (11 days vs 9 days; Conclusions: Supradiaphragmatic Roux-en-Y jejunal reconstruction after extended total gastrectomy for gastroesophageal junction adenocarcinoma is a feasible approach, associated with low complication rates and adequate recovery of quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.